AgomAb Therapeutics NV (NASDAQ:AGMB - Free Report) - Research analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of AgomAb Therapeutics in a research note issued on Monday, November 16th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($1.87) for the year, up from their prior estimate of ($1.91). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for AgomAb Therapeutics' current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for AgomAb Therapeutics' FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.72) EPS, FY2029 earnings at ($1.77) EPS and FY2030 earnings at ($1.75) EPS.
Several other equities research analysts have also weighed in on AGMB. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a "buy" rating and a $34.00 price objective on the stock. Cantor Fitzgerald started coverage on AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an "overweight" rating for the company. Wall Street Zen lowered AgomAb Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, September 27th. Piper Sandler assumed coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an "overweight" rating and a $60.00 price target on the stock. Finally, Johnson Rice reiterated a "buy" rating on shares of AgomAb Therapeutics in a research report on Wednesday, October 21st. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $37.50.
Get Our Latest Research Report on AgomAb Therapeutics
AgomAb Therapeutics Stock Down 0.8%
Shares of NASDAQ:AGMB opened at $5.92 on Wednesday. AgomAb Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $17.82. The firm has a 50-day simple moving average of $9.20 and a 200 day simple moving average of $11.67.
Insiders Place Their Bets
In other news, Director David Epstein bought 15,000 shares of the firm's stock in a transaction on Thursday, November 5th. The stock was purchased at an average price of $6.90 per share, for a total transaction of $103,500.00. Following the transaction, the director owned 40,000 shares in the company, valued at approximately $276,000. This trade represents a 60.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Pierre Kemula purchased 10,000 shares of the company's stock in a transaction on Tuesday, October 6th. The stock was purchased at an average price of $8.59 per share, for a total transaction of $85,900.00. Following the purchase, the chief financial officer directly owned 10,000 shares of the company's stock, valued at $85,900. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 70,980 shares of company stock worth $549,262.
AgomAb Therapeutics Company Profile
(
Get Free Report)
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company's pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn's disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AgomAb Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AgomAb Therapeutics wasn't on the list.
While AgomAb Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.